卫材新型抗癌药Lenvima获日本批准，将成为甲状腺癌临床治疗新标准

2015年3月26日讯/生物谷BIOON/--卫材（Eisai）新型口服抗癌药Lenvima（lenvatinib）近日喜获日本批准用于不可切除性甲状腺癌的治疗。这也是该药继今年2月获美国批准之后，攻下的又一重要市场。此前，lenvatinib在美国、日本、欧盟均被授予孤儿药地位及优先审查资格。该药作为一种具有重大公共卫生利益的创新药物，将帮助解决甲状腺癌领域存在的严重未满足的医疗需求。
卫材表示，Lenvima将成为不可切除性甲状腺癌临床治疗的新标准。业界对Lenvima非常看好，预计该药将成为卫材新的摇钱树，年销售峰值将突破10亿美元。
根据卫材官方信息，在一项大型III期SELECT研究中，与安慰剂相比，lenvatinib显著延长了放射性碘难治性分化型甲状腺癌的无进展生存期（PFS：18.3个月vs3.6个月）；同时，lenvatinib治疗组有显著更高比例的患者实现肿瘤体积缩小（65%vs2%）。此外，在日本开展的另一项II期研究中，lenvatinib针对甲状腺髓样癌和未分化型甲状腺癌也表现出了很好的疗效和耐受性。
基于这些结果，Lenvima获日本监管机构批准，成为治疗不可切除性甲状腺癌（包括分化型甲状腺癌、甲状腺髓样癌、未分化型甲状腺癌）的首个分子靶向治疗药物。
当前，尽管大多数类型的甲状腺癌能够治疗，而一旦恶化鲜有治疗方案可供选择。分化型甲状腺癌（DTC）是最常见的甲状腺恶性肿瘤，近年来发病率稳步上升。
Lenvatinib是一种口服多受体酪氨酸激酶（RTK）抑制剂，具有新颖的结合模式，除抑制参与肿瘤增殖的其他促血管生成和致癌信号通路相关RTK外，还能够选择性抑制血管内皮生长因子（VEGF）受体的激酶活性。目前，卫材也正在评估lenvatinib用于其他类型肿瘤的治疗，包括肝癌、肾细胞癌、非小细胞肺癌等，该药在日本、欧盟及其他国家的监管审查正在进行中。
英文原文：EISAIRECEIVESAPPROVALINJAPANFORANTICANCERAGENTLENVIMA®(LENVATINIBMESYLATE)ASTREATMENTFORUNRESECTABLETHYROIDCANCER
EisaiCo.,Ltd.(Headquarters:Tokyo,CEO:HaruoNaito,“Eisai”)announcedtodaythatithasreceivedmanufacturingandmarketingauthorizationinJapanforitsin-housedevelopednovelanticanceragentLenvima®(lenvatinibmesylate)indicatedforthetreatmentofunresectablethyroidcancer.
InaglobalPhaseIIIstudy(theSELECTstudy)ofLenvimaindifferentiatedthyroidcancer,Lenvimademonstratedastatisticallysignificantextensioninprogressionfreesurvivalandimprovedresponseratescomparedtoplacebo1.
IntheSELECTstudy,thefivemostcommonLenvimatreatment-relatedadverseeventsofanygradewerehypertension,diarrhea,fatigueorasthenia,decreasedappetite,andweightloss.Furthermore,aPhaseIIstudy(Study208)conductedinJapansuggestedefficacyandtolerabilityofLenvimainmedullarythyroidcarcinomaandanaplasticthyroidcarcinomaaswell2.
Duetotheresultsofthesestudies,LenvimaisthefirstmoleculartargetedtreatmentinJapanapprovedwithanindicationforunresectablethyroidcancerwhichcoversdifferentiatedthyroidcanceraswellasmedullarythyroidcarcinomaandanaplasticthyroidcarcinoma.
ThenumberofpatientswiththyroidcancerinJapanisestimatedtobebetween13,000and29,000.Althoughtreatmentispossibleformosttypesofthyroidcancer,therearefewtreatmentoptionsavailableforunresectablethyroidcancerandsothereisapressingneedforthedevelopmentofnewtreatmentoptions.Withahighdegreeofclinicalmalignancyandaprognosisamongtheworstofalltypesofcancer,anaplasticthyroidcarcinomainparticularisadiseasewithsignificantunmetmedicalneeds.
Throughthisapproval,EisaihopesthatLenvimawillmakeacontributiontopatientsasanewstandardtreatmentforunresectablethyroidcancer,whichhasnoestablishedstandardtreatmentinJapanatpresent.
LenvimaisanorallyadministeredmoleculartargetedagentthatselectivelyinhibitstheactivitiesofseveraldifferentmoleculesincludingVEGFR,FGFR,RET,KITandPDGFR.Inparticular,theagentsimultaneouslyinhibitsVEGFR,FGFRandalsoRETwhichareespeciallyinvolvedintumorangiogenesisandproliferationofthyroidcancer.
Furthermore,LenvimahasbeenconfirmedthroughX-rayco-crystalstructuralanalysistodemonstrateanewbindingmode(TypeV)toVEGFR2,andexhibitsrapidbindingtothetargetmoleculeandpotentinhibitionofkinaseactivity,accordingtokineticanalysis.
LenvimawaslaunchedintheUnitedStatesindicatedforthetreatmentoflocallyrecurrentormetastatic,progressive,radioactiveiodine-refractorydifferentiatedthyroidcancerinFebruary2015.Currently,theagentisundergoingregulatoryreviewintheEU,aswellasSwitzerland,SouthKorea,Canada,Singapore,Russia,AustraliaandBrazil.Furthermore,EisaiisconductingaglobalPhaseIIItrialofLenvimainhepatocellularcarcinomaaswellasPhaseIIstudiesofLenvimainseveralothertumortypessuchasrenalcellcarcinomaandnon-smallcelllungcancer.
InadditiontoprovidingLenvimaasanewtreatmentoptionforthyroidcancer,inaccordancewiththeconditionsofapproval,EisaiwillworkafterlaunchtocarryoutanobservationalstudyandpromotetheappropriateuseofLenvima.EisaiiscommittedtoexploringthepotentialclinicalbenefitsofLenvimainordertofurthercontributetopatientswithcancer,andtheirfamilies.
医药网新闻